- Apellis Pharmaceuticals (APLS, Financial) appoints Craig Wheeler to its Board of Directors, effective immediately.
- Craig Wheeler has extensive experience in the biopharmaceutical industry, having led Momenta Pharmaceuticals for 14 years.
- Wheeler is recognized for his successful leadership in product launches and company growth.
Apellis Pharmaceuticals, Inc. (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, the founder and CEO of Headwaters Biotech Advisors, is a seasoned executive with over 30 years of leadership experience in the biopharmaceutical industry. His new role at Apellis marks a significant addition to the company’s leadership team.
Craig Wheeler’s illustrious career includes a 14-year tenure as president and CEO of Momenta Pharmaceuticals, where he guided the company through numerous product launches and its eventual acquisition by Johnson and Johnson in 2020. Prior to his time at Momenta, Wheeler served as president of Chiron Biopharmaceuticals, overseeing a global business unit with approximately 2,500 employees.
In addition to his new role at Apellis, Wheeler currently serves on the Board of Directors of Amicus Therapeutics and is deeply involved in the biopharmaceutical community. He holds an MBA from the Wharton School of the University of Pennsylvania and both a BS and MS in Chemical Engineering from Cornell University.
Apellis, known for pioneering treatments in complement medicine, views Wheeler’s extensive expertise as a valuable asset. “Craig is a seasoned leader, who has successfully grown biopharmaceutical companies into strong commercial organizations with robust pipelines,” said Cedric Francois, M.D., Ph.D., Apellis CEO and co-founder.
The addition of Wheeler is expected to bolster Apellis’s strategic initiatives as the company continues to innovate in developing therapies for serious diseases. For more information about Apellis, please visit their official website or follow them on social media platforms such as X and LinkedIn.